Some analysts say they expect Danaher will be more aggressive with mergers and acquisitions following the Veralto spin-off, which may also be a catalyst for DHR stock. The company continues to post strong earnings, including results for this year’s second quarter that beat Wall Street forecasts. 15 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Danaher in the last twelve months.
An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Plus, DHR info will be updated daily in your Zacks.com Portfolio Tracker – also free. Upgrade to MarketBeat All Access to add more stocks to your watchlist.
With his visionary approach, Rales has steered the company towards sustained growth and innovation. Rainer M. Blair holds the positions of President, Chief Executive Officer, and Director, leading Danaher’s day-to-day operations and spearheading its growth strategies. Blair’s dynamic leadership has been crucial in driving the company’s expansion and ensuring its position as a market leader. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.
- Danaher’s stock is owned by many different institutional and retail investors.
- Concerns about breaking up Danaher’s core businesses primarily caused the decline.
- 27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com.
- For the full year, the company expects a decline in the high-single to low-double-digits range.
- Danaher is involved in designing, manufacturing, and marketing a broad array of products and services.
Danaher caters to various markets, including healthcare, life sciences, diagnostics, environmental monitoring, and industrial automation. Its products and services find applications in research institutions, healthcare facilities, industrial manufacturers, and government organizations. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year.
Should You Invest in the Invesco Water Resources ETF (PHO)?
Danaher is involved in designing, manufacturing, and marketing a broad array of products and services. Its offerings span medical diagnostics equipment, life sciences and diagnostics tools, environmental solutions, water quality analysis systems, industrial automation tools, and other specialized instruments. Danaher’s mission is to leverage its technological expertise and commitment to continuous improvement to develop innovative solutions that enhance human well-being and drive sustainable growth. Healthcare is a sector that has underperformed the broader stock market this year. The S&P 500 Health Care Sector Index is down over 2.50% year-to-date versus a 17% gain in the benchmark S&P 500 index.
There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “moderate buy” DHR shares. Danaher has ample growth opportunities, including expansion into emerging markets, strategic acquisitions, and research and development investments. The company’s strong focus on continuous improvement and customer-centric solutions will drive its pursuit of growth opportunities. Danaher’s valuation metrics demonstrate positive investor sentiment and confidence in the company’s future growth prospects. Its favorable price-to-earnings ratio and price-to-cash flow ratio reflect investor willingness to pay a premium for its earnings potential and cash generation capacity.
In the first six months of 2023, foreign currency headwinds adversely impacted net sales by 1.5%.The negativity surrounding the stock is evident from the Zacks Consensus Estimate for 2023 earnings being revised downward by 5.8% in the past 60 days. As of August 31st, there was short interest totaling 6,330,000 shares, an increase of 29.2% from the August 15th total of 4,900,000 shares. Based on an average daily trading volume, of 2,740,000 shares, the short-interest ratio is currently 2.3 days. Danaher has displayed excellent financial performance in recent years, with consistent revenue growth and profitability. The company’s financial stability and strategic acquisitions have contributed to its robust performance. Danaher’s strong financials indicate its ability to generate revenue and profits, which has positively influenced investor sentiment and contributed to its favorable valuation.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. DHR’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. He spent five years as a staff reporter at The Wall Street Journal, and has also written for The Washington Post and Toronto Star newspapers, as well as financial websites such as The Motley Fool and Investopedia.
- The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
- There are currently 4 hold ratings and 11 buy ratings for the stock.
- The decline has been broad-based as investors focus their capital allocations on high-flying technology stocks at the expense of pharmaceutical companies, medical device manufacturers and health insurers.
- Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.
- Danaher caters to various markets, including healthcare, life sciences, diagnostics, environmental monitoring, and industrial automation.
- The decline brought valuations down following the Covid-19 pandemic when some of the best-performing stocks in the world were those of pharma companies and other healthcare companies racing to find a cure to the respiratory disease.
One share of DHR stock can currently be purchased for approximately $252.45. 27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com. Rainer M. Blair has an approval rating of 98% among the company’s employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
Here’s How Much You Would Have Made Owning Danaher Stock In The Last 10 Years
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Investors of record on Thursday, October 12th will be given a dividend of $0.27 per share on Friday, October 27th.
According to 16 analysts, the average rating for DHR stock is “Buy.” The 12-month stock price forecast is $282.27, which is an increase of 11.81% from the latest price. Investors should closely monitor any recent news or events that https://1investing.in/ may have impacted Danaher’s share price, such as industry developments or major acquisitions. Its competitive advantages, including a broad product portfolio and emphasis on innovation, position it well within its industries.
Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business. Compare
DHR’s historical performance
against its industry peers and the overall market.
Danaher’s stock performance has been noteworthy, driven by its strong financials, strategic initiatives, and positive market sentiment. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
However, its proactive risk management strategies mitigate potential impacts on the company’s financial performance. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Looking ahead, Medtronic, which makes pacemakers, catheters and other devices, said it now expects its full-year profit in 2023 to be between $5.08 and $5.16 a share, up from a previous range of $5 to $5.10.
Morningstar analysts hand-select direct competitors or comparable companies to
provide context on the strength and durability of DHR’s
competitive advantage. Provides a general description of the business conducted by this company. The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction. Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
The escalating cost of sales poses a threat to Danaher’s bottom line. The company’s cost of sales increased 8.9% year over year in 2022 due to inflation in raw material costs. In the second quarter of 2023, cost of sales increased iforex live rates 2.8% year over year to $3,116 million. Logistics problems and supply chain issues also remain concerns for the company.International operations expose Danaher to risks stemming from unfavorable movements in foreign currencies.
The decline has been broad-based as investors focus their capital allocations on high-flying technology stocks at the expense of pharmaceutical companies, medical device manufacturers and health insurers. The decline brought valuations down following the Covid-19 pandemic when some of the best-performing stocks in the world were those of pharma companies and other healthcare companies racing to find a cure to the respiratory disease. That provides investors with a long time horizon, an opportunity to pick up some great healthcare stocks at reasonable, if not cheap, prices right now. Here are the three most undervalued healthcare stocks to buy in September 2023.